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Objective
To characterise the surgical feasibility and outcomes of
robot-assisted radical cystectomy (RARC) for pathological T4
bladder cancer.
Patients and Methods
Retrospective evaluation of a prospectively maintained
International Radical Cystectomy Consortium database was
conducted for 1118 patients who underwent RARC between
2003 and 2012.
We dichotomised patients based on pathological stage (≤pT3
vs pT4) and evaluated demographic, operative and
pathological variables in relation to morbidity and mortality.
Results
In all, 1000 ≤pT3 and 118 pT4 patients were evaluated. The
pT4 patients were older than the ≤pT3 patients (P = 0.001).
The median operating time and blood loss were 386 min
and 350 mL vs 396 min and 350 mL for p T4 and ≤pT3,
respectively.
The complication rate was similar (54% vs 58%; P = 0.64)
among ≤pT3 and pT4 patients, respectively. The overall 30-
and 90-day mortality rate was 0.4% and 1.8% vs 4.2% and
8.5% for ≤pT3 vs pT4 patients (P < 0.001), respectively.
The body mass index (BMI), American Society of
Anesthesiology score, length of hospital stay (LOS) >10 days,
and 90-day readmission were signiﬁcantly associated with
complications in pT4 patients.
Meanwhile, BMI, LOS >10 days, grade 3–5 complications,
90-day readmission, smoking, previous abdominal surgery and
neoadjuvant chemotherapy were signiﬁcantly associated with
mortality in pT4 patients. On multivariate analysis, BMI was
an independent predictor of complications in pT4 patients,
but not for mortality.
Conclusions
RARC for pT4 bladder cancer is surgically feasible but entails
signiﬁcant morbidity and mortality.
BMI was independent predictor of complications in pT4 patients.
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Introduction
Although radical cystectomy (RC) and pelvic lymph node
(LN) dissection is well established as the ‘gold-standard’
treatment for muscle-invasive and high-risk non-muscle-
invasive bladder cancer [1], the management of locally
advanced bladder cancer continues to be controversial. In the
absence of local treatment, locally advanced bladder cancer
can lead to adverse pelvic and urinary symptomology, in
addition to disease progression, and such local symptoms
signiﬁcantly decreases patient quality of life [2]. Accordingly, it
has been suggested that patients with locally advanced bladder
cancer may beneﬁt from RC as a palliative procedure or as
part of a multimodality attempt towards curative intent [3,4].
However, due to signiﬁcant reported morbidity and mortality
of open RC in the setting of locally advanced bladder cancer,
local extirpation has been questioned [5].
Robot-assisted RC (RARC) has emerged as an alternative
approach to open RC based on an improved proﬁle in terms
of blood loss, transfusion rate, need for postoperative
analgesia, recovery of bowel function, and length of hospital
stay (LOS) [6–8]. Prior to the present study, the application of
a robot-assisted approach to locally advanced bladder cancer
has not been appropriately assessed due to previous selection
bias for low-volume and LN-negative disease. It has been
questioned whether the robot-assisted approach may lead to
inferior outcomes in this setting due to a lack of tactile
sensation, which may aid in avoiding positive surgical margins
and in achieving complete resection.We sought to characterise
the feasibility and surgical outcomes of RARC for pathological
T4 bladder cancer.
Patients and Methods
A retrospective analysis of the prospectively maintained
database of the International Robotic Cystectomy Consortium
(IRCC), a collaborative eﬀort of over 20 institutions
comprising ≈1300 patients treated with RARC for bladder
cancer, was performed.We dichotomised patients based on
pathological tumour stage into patients with ≤pT3 and pT4
tumours.
Speciﬁc clinical and pathological data was collected and
analysed for patients which included: demographic variables
(age, gender, body mass index [BMI], American Society of
Anesthesiology [ASA] score, and smoking), preoperative
disease characteristics (preoperative chemotherapy, abdominal
surgery, and radiation), operative variables (estimated blood
loss [EBL], LOS, length of intensive care unit (ICU) stay, type
of diversion, and technique of diversion; intracorporeal vs
extracorporeal), pathological characteristics (tumour stage, LN
yield, and number of positive LNs), and 90-day postoperative
outcomes (complications, readmission and mortality).
Patient comorbidity was assessed preoperatively using the ASA
score. Complications were identiﬁed, deﬁned and classiﬁed
using the modiﬁed Clavien system [9]. The technique of
RARC and pelvic LN dissection varied according to the
individual surgeon and institution. Urinary diversion was
performed both by intracorporeal and extracorporeal
techniques.
Descriptive statistics, such as frequencies and relative
frequencies, were computed for all categorical outcomes.
Numeric outcomes were summarised using summary statistics
such as the mean, standard deviation (SD), range, etc.
Associations between baseline characteristics and pathological
stage were statistically assessed using Fisher’s exact test for
categorical outcomes, and Wilcoxon rank-sum test for
continuous outcomes. Univariate and multivariate logistic
regression models were ﬁt to evaluate preoperative, operative
and postoperative predictors of readmission, complication and
mortality. All statistical analysis was performed using SAS
software (version 9.3, SAS Institute Inc., Cary, NC, USA). All
tests were two-side, with statistical signiﬁcance deﬁned as
P < 0.05.
Results
In all, 1000 ≤pT3 and 118 pT4 patients were analysed. The
pT4 patients were older than the ≤pT3 patients, at a mean of
70 and 67 years, respectively (P = 0.001). Both groups were
comparable for gender, ASA score, rates of prior abdominal
surgery or neoadjuvant chemotherapy, LOS, EBL and
operating time. The intraoperative blood transfusion rate was
signiﬁcantly higher among pT4 patients compared with ≤pT3
patients, at 12% vs 4%, respectively (P = 0.049).
There were statistically signiﬁcant diﬀerences between ≤pT3
and pT4 patients for BMI (27.8 and 26.3 kg/m2, respectively;
P = 0.008), and salvage cystectomy after radiation (1.4% and
5.9%, respectively; P < 0.001).
The mean number of LNs removed was not signiﬁcantly
diﬀerent between ≤pT3 and pT4 patients (19.2 vs 17.3,
respectively; P = 0.145); however, more pT4 patients had
positive LNs (55% vs 23%; P < 0.001). The rate of positive
surgical margin at cystectomy was 4% and 31.5% (P = 0.001)
for ≤pT3 and pT4 patient, respectively.
The mean follow-up time for pT4 and ≤pT3 patients was 10.6
and 17 months, respectively (P < 0.001). The pT4 patients
underwent ileal conduit more often than the ≤pT3 patients
(87% vs 66%; P < 0.001). The length of ICU stay was 1 day
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and 1.8 days for ≤pT3 and pT4 patient, respectively (P <
0.001). The complication rate was similar between ≤pT3 and
pT4 patients (54% vs 58%) with 19.0% and 20% of the
complications being Clavien grade ≥3, respectively. The 90-day
readmission was similar. The overall 30- and 90-day mortality
rate was 0.4% and 1.8% vs 4.2% and 8.5% for ≤pT3 and pT4
patients, respectively (P < 0.001; Table 1).
On univariate analysis, BMI, ASA score, LOS >10 days, and
90-day readmission were signiﬁcantly associated with
complications in pT4 patients (Table 2). However, on
multivariate analysis, only BMI was an independent predictor
of complications in pT4 patients (Table 2). Meanwhile, on
univariate analysis BMI, LOS >10 days, Clavien grade 3–5
complications, 90-day readmission, smoking, previous
Table 1 Patient demographics.
Pathological stage ≤3 Pathological stage 4 P
Preoperative characteristics
Overall number of patients 1000 118
Age, years 0.001
mean (SD) 67 (0.4) 70 (0.9)
median (range) 68.0 (26–90) 72.0 (28–90)
Male gender, % 80 76 0.40
BMI, kg/m2:
mean (SD) 27.8 (0.2) 26.3 (0.5) 0.01
Obese (>30 kg/m2), n (%) 78 (9) 9 (8) 0.90
ASA score ≥3, n (%) 578 (58) 77 (66) 0.12
Neoadjuvant chemotherapy, n (%) 139 (14) 17 (14) 0.90
Clinical stage, n (%) <0.001
≤T2 673 (93) 63 (76)
>T2 52 (7) 20 (24)
Preoperative radiation, n (%) 14 (1.4) 7 (5.9) <0.001
Prior abdominal surgery, n (%) 421 (42) 46 (39) 0.52
Diversion type, n (%): <0.001
ileal conduit 659 (66) 103 (87)
continent 341 (34) 15 (13)
Diversion location, n (%): 0.625
intracorporeal 755 (76) 94 (80)
extracorporeal 208 (21) 22 (19)
Pathological outcomes
Positive surgical margins, n (%) 43 (4.4) 34 (31.5) <0.001
LN positive, n (%) 228 (23) 65 (55) <0.001
LN yield: 0.15
mean (SD) 19.2 (0.4) 17.3 (1.1)
median (range) 18 (0.0–74.0) 17 (0.0–54.0)
Follow-up, months: <0.001
mean (SD) 17.0 (0.6) 10.6 (1.2)
median (range) 11 (0.0–85.0) 6 (0.0–61)
Perioperative outcomes
Overall operating time, min 0.47
mean (SD) 406.0 (3.9) 394.6 (9.6)
median (range) 396 (50.0–862) 386 (0.0–618)
EBL, mL: 0.47
mean (SD) 450.9 (12.1) 522.8 (51.5)
median (IQR) 350.0 (0.0–3900) 350.0 (0.0–3700)
Intraoperative transfusion, n (%) 10 (4.0) 4 (11.8) 0.049
ICU stay, days: <0.001
mean (SD) 1.0 (0.1) 1.8 (0.4)
median (IQR) 0.0 (0–36) 1.0 (0–21)
Hospital stay, days: 0.84
mean (SD) 11.1 (0.3) 11.1 (0.7)
median (IQR) 9.0 (0–78) 9.0 (1–57)
Complications, n (%) 0.64
Clavien 1–2 349 (35) 45 (38)
Clavien 3–5 190 (19) 24 (20)
Readmission, n (%) 0.32
30 days 114 (11) 9 (8)
90 days 174 (17.4) 23 (19.5)
Mortality, n (%) <0.001
30 days 4 (0.4) 5 (4.2)
90 days 18 (1.8) 10 (8.5)
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abdominal surgery, ileal conduit diversion and neoadjuvant
chemotherapy were signiﬁcantly associated with overall
mortality in pT4 patients. On multivariate analysis, BMI was
an independent predictor of complications in pT4 patients,
but not an independent predictor for mortality (Tables 2,3).
Discussion
To date, only small case series have been reported regarding
RC in pT4 bladder cancer, and data about cancer outcomes
are sparse, and no reports speciﬁcally address eﬃciency of
RARC in locally advanced bladder cancer [10,11].
Long-term survival is dismal when bladder cancer invades the
pelvic sidewall or adjacent structures, yet RC can provide
palliation and accurate staging [12]. The rationale behind
advocating RC in locally advanced disease could be explained
by increasing evidence supporting meticulous surgical
clearance with extended lymphadenectomy both of which
can signiﬁcantly impact disease-free survival [13]. Hence,
‘debulking’ surgery may have oncological beneﬁt in bladder
cancer, as is well established in other malignancies, e.g. ovarian
cancer. In the randomised Southwest Oncology Group
(SWOG) trial in which neoadjuvant chemotherapy followed
by RC compared with RC alone showed a survival beneﬁts in
patients who received neoadjuvant chemotherapy with T2
disease (105 vs 75 months; P = 0.05) and for T3 or T4a disease
(65 vs 24 months; P = 0.05) [3]. The data for adjuvant
chemotherapy are less compelling. However, beneﬁts may be
derived for patients who progress to extensive disease [14,15].
Neoadjuvant chemotherapy was administered to 14.4%
patients in present cohort, despite proved eﬃcacy.
The present outcomes show that operating time, EBL and LOS
were comparable between pT4 and ≤pT3 patients. These
ﬁndings support similar observations by Hayn et al. [16] who
reported an EBL of 400 mL, operating time of 6.3 h and LOS
of 8 days. The present overall 90-day complication rate was
not higher among pT4 patients; however, 90-day mortality
was. The present complication rates were similar to those in
previously published RARC series, although the high-grade
complications were higher [7,8]. Pruthi et al. [17] reported
major surgical complications (Clavien grade ≥3) in 8% of their
Table 2 Univariable and multivariable logistic regression analysis to
evaluate variables associated with 90-day complications.
Variable 90-Day complications
OR (95% CI) P
Preoperative variables – univariable analysis
Gender (female vs male) 1.0 (0.43–2.34) 1.000
Age at surgery (10-year interval) 1.1 (0.72–1.58) 0.744
BMI (kg/m2) 1.1 (1.04–1.22) 0.005
Obese (BMI >30 kg/m2, yes/no) 8.0 (0.97–66.34) 0.054
Preoperative chemotherapy (yes/no) 1.2 (0.41–3.22) 0.79
Current smoker (yes/no) 2.42 (0.98–5.98) 0.06
ASA 3–4 vs 1–2 0.50 (0.23–1.09) 0.08
Preoperative variables – multivariable analysis
Gender (male vs female) 1.30 (0.43–3.92) 0.65
Age at surgery (10-year interval) 1.20 (0.72–1.99) 0.49
BMI (kg/m2) 1.12 (1.02–1.22) 0.02
Current smoker (yes/no) 2.90 (0.98–8.68) 0.06
ASA (1–2 vs 3–4) 0.34 (0.12–1.02) 0.05
Preoperative chemotherapy (yes/no) 0.90 (0.25–3.10) 0.85
Intraoperative variables – univariable analysis
Operating room time (≤6 vs >6 h) 0.58 (0.27–1.25) 0.16
EBL (≤800 vs >800 mL) 3.0 (0.90–10.10) 0.08
Type of urinary diversion (continent vs conduit) 0.63 (0.21–1.90) 0.41
Location of diversion (intra vs extracorporeal) 2.50 (0.95–6.80) 0.03
Intraoperative variables – multivariable analysis
Operating room time (≤6 vs >6 h) 0.58 (0.26–1.30) 0.19
EBL (≤800 vs >800 mL) 3.26 (0.93–11.40) 0.06
Type of urinary diversion (continent vs conduit) 2.69 (0.93–7.77) 0.06
Postoperative variables – univariable analysis
Hospital stay (<10 vs ≥10 days) 2.14 (1.00–4.56) 0.047
ICU stay 1.15 (0.94–1.42) 0.18
90-day readmission 32.35 (4.17–250.87) 0.0009
Postoperative variables – multivariable analysis
Hospital stay (<10 vs ≥10 days) 1.49 (0.60–3.80) 0.40
ICU stay 1.13 (0.92–1.40) 0.24
Table 3 Univariable and multivariable logistic regression analysis to
evaluate variables associated with 90-day mortality.
Variable 90-Day mortality
OR (95% CI) P
Preoperative variables – univariable analysis
Gender (female vs male) 0.98 (0.41–2.34) 0.96
Age at surgery (10-year interval) 1.04 (0.70–1.55) 0.85
BMI (kg/m2) 1.10 (1.02–1.20) 0.013
Obese (BMI >30 kg/m2, yes/no) 3.40 (0.80–14.43) 0.096
Preoperative chemotherapy (yes/no) 3.35 (1.14–9.84) 0.028
Current smoker (yes/no) 3.29 (1.23–8.80) 0.018
ASA 3–4 vs1–2 1.69 (0.76–3.78) 0.20
Prior abdominal surgery 2.38 (1.10–5.13) 0.027
Preoperative variables – multivariable analysis
Gender (male vs female) 1.20 (0.42–3.46) 0.76
Age at surgery (10-year interval) 1.09 (0.65–1.82) 0.75
BMI (kg/m2) 1.07 (0.99–1.16) 0.11
Current smoker (yes/no) 2.69 (0.90–8.10) 0.08
ASA (1–2 vs 3–4) 1.16 (0.44–3.10) 0.77
Preoperative chemotherapy (yes/no) 2.32 (0.69–7.71) 0.17
Intraoperative variables – univariable analysis
Operating room time (≤6 vs >6 h) 0.70 (0.32–1.54) 0.38
EBL (≤800 vs >800 mL) 1.82 (0.61–5.45) 0.29
Type of urinary diversion (continent vs conduit) 0.20 (0.04–0.93) 0.04
Location of diversion (intra vs extracorporeal) 1.30 (0.53–3.423) 0.54
Intraoperative variables – multivariable analysis
Operating room time (≤6 vs >6 h) 0.63 (0.28–1.43) 0.27
EBL (≤800 vs >800 mL) 2.19 (0.70–6.77) 0.17
Type of urinary diversion (continent vs conduit) 1.38 (0.52–3.68) 0.52
Postoperative variables – univariable analysis
Hospital stay (<10 vs ≥10 days) 2.60 (1.20–5.60) 0.015
ICU stay 1.10 (0.95–1.27) 0.19
90-day readmission 3.39 (1.29–8.92) 0.013
Complications
Clavien 0 vs 3–5 0.15 (0.049–0.45) 0.0007
Clavien 1–2 vs Clavien 3–5 0.67 (0.24–1.87) 0.45
Postoperative variables – multivariable analysis
Hospital stay (<10 vs ≥10 days) 1.22 (0.47–3.14) 0.66
ICU stay 1.10 (0.92–1.25) 0.40
Complications
Clavien 0 vs 3–5 0.11 (0.01–1.47) 0.10
Clavien 1–2 vs Clavien 3–5 0.74 (0.23–2.33) 0.25
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patients, with 13% of patients having non-organ-conﬁned
disease. Higher mortality and high-grade complications in the
present series could be explained by the advanced nature of
the disease in our series, which has not been addressed in
RARC literature and the multi-institutional nature of our
series, which represent variation in operative expertise, patient
selection, and quality of perioperative care. In the present
study, there was no diﬀerence in 90-day readmission between
≤pT3 and pT4 patients. Stimson et al. [18] reported a 90-day
readmission rate of 26.6%, which was slightly higher than our
present pT4 patients (19.5%) for the same period.
In a study by Nagele et al. [10], 20 patients underwent RC for
locally advanced bladder cancer (T4a/b), the LOS was 19 days,
50% of patients received an intraoperative blood transfusion
and 50% died within a mean (range) interval of 7 (2–19)
months. Furthermore, Hemal et al. [11] evaluated the
feasibility of laparoscopic RC for loco-regionally advanced
bladder cancer in 13 patients and reported a 57% blood
transfusion rate, LOS was 11 days, and there was one mortality
at ≤30 days.
In all, 45% of patients with pT4 disease in the present study
underwent a LN dissection with negative LNs and a mean
LN yield of 17, similar to Tilki et al. [19] who reported 54%
incidence of LN metastasis in pT4 bladder cancer. The
impact of LN metastasis on survival after RC was reported
by Shariat et al. [20] who found that in patients with
non-organ-conﬁned and LN-negative disease the
progression-free survival (PFS) and cancer-speciﬁc survival
(CSS) were 55% and 59%, respectively, compared with
patients with LN metastasis, where PFS and CSS were only
29% and 37%, respectively.
Local cancer control in terms of total resection is an
important predictor of survival in patients with pT4, as
patients with positive margins are signiﬁcantly more likely to
have disease recurrence, as demonstrated by Dotan et al. [21].
In the present study, 31.5% of pT4 patients had positive
margins compared with 24% reported in an open RC series
by Novara et al. [22] and 25% by Tilki et al. [19]. Due to
limitation of data, sites of positive margins could not be
deﬁned.
One of the primary aims of the present study was to identify
predictors of complications and mortality in pT4 patients
after RARC. BMI was the only independent predictor of
complications. Reyes et al. [23] reported a higher incidence of
infection-related complications in patients with higher BMI.
Kouba et al. [24] found more stomal complications after RC
and ileal conduit diversion in obese patients. In contrast, Poch
et al. [25] found that RARC and intracorporeal ileal conduit
was feasible for overweight and obese patients compared with
patients with normal BMI, and other investigators have found
no association between BMI and complications after RC,
including RARC [26].
The present study has its limitations. First, the limitations
inherent to retrospective analysis. Given the large number of
surgeons and their variability, selection and reporting bias
might have inﬂuenced the results. Second, most surgeons in
the IRCC had previous experience in robot-assisted surgery.
Thus, results might not be applicable to all urological
surgeons. Third, the number of patients varied widely among
the institutions. Thus, the overall outcomes might have been
inﬂuenced by data from the institutions with greater
experience. It is crucial to consider the economic impact
of robot use to fully evaluate this approach; however, the
present data are lacking regarding the cost. Finally, we
did not have prospective data on outcomes for functional
status and quality of life outcomes. Additional follow-up is
needed to assess any long-term oncological or survival
outcomes.
In conclusion, RARC for locally advanced bladder cancer is
surgically feasible with signiﬁcant morbidity and mortality.
BMI was found to be an independent predictor of
complications in pT4 patients.
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